MHLW Warns Use Of Chugai’s Pegasys In Patients With Interstitial Pneumonia
This article was originally published in PharmAsia News
The Ministry of Health, Labor and Welfare has ordered Chugai Pharmaceutical to change labeling for interferon drug Pegasys (peginterferon Alfa-2a) for hepatitis C. MHLW contraindicated the use of the drug on patients with history of interstitial pneumonia. The decision is based on a comparison to other drugs; a higher hepatitis recurrence rate was reported among Pegasys patients with a history of interstitial pneumonia. (Click here for more - Japanese language
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.